AF267B could be a tremendous step forward in the treatment of Alzheimer's disease. Not only does it appear to work on the pathology of Alzheimer's and ease its symptoms, it crosses the blood-brain barrier, which means it does not have to be directly administered to the brain, a significant advantage for a pharmaceutical product. Although we cannot determine what the effects of AF267B will be in humans until clinical trials are complete, we are very excited by the results our study has yielded. |
I am honored to receive this award and thankful to MetLife Foundation for supporting basic research in this important field. Alzheimer's disease is a devastating neurological disorder that affects millions of people and has a significant impact on our economy. We need to invest more in basic research so that we have the tools to understand and ultimately treat this disease. |
It's been known for about 30 years that there's a selective loss of neurons in the brains of Alzheimer's patients, neurons that produce a neurotransmitter chemical called acetylcholine. |